BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	65.22	193.73	232.97	213.12	32.43
Cash & Cash Equivalents	65.22	193.73	232.97	213.12	32.43
Cash Growth	-66.33%	-16.84%	9.31%	557.25%	-23.82%
Receivables	0.07	0.25	0	0	0
Inventory	1.99	1.99	0	0	0
Other Current Assets	4.86	6.91	3.84	3.95	1.68
Total Current Assets	72.14	202.87	236.81	217.07	34.11
Property, Plant & Equipment	1.47	2.06	2.54	2.78	2.23
Other Long-Term Assets	0.09	0.93	0.09	0.09	0.05
Total Long-Term Assets	1.56	2.99	2.63	2.87	2.29
Total Assets	73.7	205.85	239.44	219.94	36.39
Accounts Payable	13.76	10.65	4.88	4.14	4.95
Other Current Liabilities	13.51	22.25	11.79	7.71	3.52
Total Current Liabilities	27.27	32.9	16.67	11.84	8.47
Long-Term Debt	101.04	93.84	1.11	1.4	1.03
Other Long-Term Liabilities	1.91	2.34	0	0	0
Total Long-Term Liabilities	102.94	96.18	1.11	1.4	1.03
Total Liabilities	130.21	129.08	17.77	13.24	9.5
Total Debt	101.04	93.84	1.11	1.4	1.03
Debt Growth	7.67%	8392.04%	-20.96%	35.86%	-
Retained Earnings	-590.6	-411.55	-245.79	-138.86	-56.69
Shareholders' Equity	-56.51	76.78	221.67	206.7	26.9
Net Cash / Debt	-35.82	99.89	231.86	211.72	31.4
Net Cash / Debt Growth	-	-56.92%	9.51%	574.34%	-26.24%
Net Cash Per Share	-1.23	3.57	8.79	9.76	1.93
Working Capital	44.88	169.97	220.15	205.22	25.64
Book Value Per Share	-1.94	2.74	8.40	9.53	1.65

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).